Welcome to our dedicated page for CVRx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. Chief Revenue Officer John Robert Allen reported a mix of stock sales and awards. He sold 3,964 shares of common stock in an open-market transaction at a weighted average price of $7.9025 per share to cover tax withholding obligations from equity awards. He also received a grant of 35,000 restricted stock units and 52,000 stock options, both vesting over several years starting on February 27, 2027, increasing his long-term equity exposure to the company.
CVRx, Inc. chief operating officer Brent Binkowski reported equity awards on February 27, 2026. He received 23,000 stock options with an exercise price of $0.00 per share and a separate grant of 15,000 shares of common stock, both classified as awards rather than open-market purchases.
The 15,000-share common stock grant consists of restricted stock units that vest in four equal annual installments of 25% on each anniversary of the grant date. The 23,000-stock-option award vests as to 25% of the shares on February 27, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. After these transactions, Binkowski directly owned 31,600 shares of common stock, according to the filing.
CVRx, Inc. approved a new performance stock unit (PSU) program for its executive officers tied to a cumulative revenue goal over the fiscal 2026–2027 period. This incremental award is in addition to their regular annual equity grants.
For named executive officers, the grant date value of these PSUs equals three-fourths of their 2026 annual long-term incentive value. Payouts range from 50% of target at threshold performance to 200% at maximum. Any earned PSUs vest 50% after the revenue goal is certified and 50% on December 31, 2028, generally requiring continued employment and including provisions for accelerated or continued vesting upon death, disability, certain terminations, or qualifying change in control events.
CVRx director-associated entity reports open-market share purchase. Treo Ventures I, L.P., an entity for which director Mudit K. Jain is the general partner, bought 46,800 shares of CVRx common stock on February 20, 2026 at a weighted average price of $6.3588 per share, with individual prices ranging from $5.8500 to $6.3868. Jain also directly holds 5,650 common shares after these transactions.
CVRx, Inc. director Mudit K. Jain reported an open-market purchase of 600 shares of common stock at a weighted average price of $4.6417 per share on February 18, 2026. Following this transaction, he directly holds 5,650 common shares.
In addition, 933,383 common shares are held indirectly through Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power. He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.
CVRx, Inc. is a commercial-stage medical device company focused on Barostim, a minimally invasive neuromodulation implant for patients with heart failure with reduced ejection fraction (HFrEF). Barostim is FDA-approved, has expanded labeling, and is reimbursed by Medicare in U.S. inpatient and outpatient settings.
For the year ended December 31, 2025, CVRx generated $56.7 million in revenue with an 85% gross margin, compared to $51.3 million and 84% in 2024. Net loss was $53.3 million versus $60.0 million, and the accumulated deficit reached $590.7 million, reflecting ongoing investment in commercialization and R&D.
The company estimates a U.S. prevalence-based market opportunity of $10.5 billion (339,000 patients) for current HFrEF indications, which could rise to $30.5 billion (983,000 patients) if a new pivotal IDE trial in a broader heart failure population is successful. Multiple clinical studies have shown Barostim can improve walking distance, quality of life, functional class, and key biomarkers while maintaining high safety margins.
CVRx, Inc. reported fourth quarter 2025 revenue of $16.0 million, up 4% year over year, with U.S. revenue of $14.9 million and gross margin improving to 86%. The company remained unprofitable, posting a quarterly net loss of $11.9 million, or $0.46 per share.
For full year 2025, revenue reached $56.7 million, a 10% increase, while net loss narrowed to $53.3 million from $60.0 million. CVRx expanded to 252 active implanting centers and 53 U.S. sales territories, and maintained a high 85% gross margin.
The company initiated the large BENEFIT-HF trial, targeting up to 2,500 patients and potential threefold expansion of the Barostim addressable market, with expected net costs of $20–$30 million over five to seven years. CVRx also upsized its Innovatus debt facility to up to $100 million and borrowed an additional $10 million, ending 2025 with $75.7 million in cash and cash equivalents and guiding 2026 revenue to $63.0–$67.0 million.
Johnson & Johnson, together with its subsidiary Johnson & Johnson Innovation – JJDC, Inc., reports beneficial ownership of 4,024,861 shares of CVRx, Inc. common stock, representing 15.4% of the class as of the measurement date. JJDC directly owns the shares, and Johnson & Johnson may be deemed to indirectly own them through its wholly owned subsidiary.
The ownership percentage is calculated against 26,210,109 CVRx common shares outstanding as of October 30, 2025, with the ownership position reported as of December 31, 2025. All voting and dispositive power over these shares is reported as shared rather than sole.
CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC that allows the company to offer and sell shares of its common stock in an at-the-market program. Under this arrangement, CVRx may issue shares with an aggregate offering amount of up to $50.0 million, from time to time, through Jefferies acting as sales agent.
Any sales will be made as at-the-market offerings under an effective Form S-3 shelf registration and related prospectus supplement. Jefferies will receive a commission of up to 3.0% of the gross proceeds from any shares sold, and CVRx will also cover certain related expenses. The company states that it intends to use any net proceeds primarily for working capital and general corporate purposes, and is not obligated to sell any specific amount under the agreement.
CVRx is offering up to $50,000,000 of common stock through an at-the-market program with Jefferies as sales agent. Shares may be sold from time to time on Nasdaq or other markets, with Jefferies earning a commission of up to 3% of the gross proceeds and treated as an underwriter. The company plans to use any net proceeds primarily for working capital and general corporate purposes.
At an illustrative price of $8.45 per share, CVRx assumes selling 5,917,159 shares, which would generate approximately $50.0 million in gross proceeds and increase net tangible book value from $1.68 to $2.87 per share. New investors in that scenario would see immediate dilution of $5.58 per share. As of September 30, 2025, CVRx had 26,193,733 shares outstanding, plus additional options, warrants and plan reserves that could add further dilution if exercised or issued.